Merus NV
NASDAQ:MRUS

Watchlist Manager
Merus NV Logo
Merus NV
NASDAQ:MRUS
Watchlist
Price: 46.19 USD 1.76% Market Closed
Market Cap: 3.2B USD
Have any thoughts about
Merus NV?
Write Note

Net Margin
Merus NV

-680.6%
Current
-315%
Average
-7.6%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-680.6%
=
Net Income
-244.6m
/
Revenue
35.9m

Net Margin Across Competitors

Country Company Market Cap Net
Margin
NL
Merus NV
NASDAQ:MRUS
3.2B USD
-681%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-21 040%
US
Abbvie Inc
NYSE:ABBV
320.1B USD
9%
US
Amgen Inc
NASDAQ:AMGN
147.4B USD
13%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
119.4B USD
-5%
US
Gilead Sciences Inc
NASDAQ:GILD
113.8B USD
0%
US
Epizyme Inc
F:EPE
94.1B EUR
-392%
AU
CSL Ltd
ASX:CSL
135.4B AUD
18%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.6B USD
34%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
NL
argenx SE
XBRU:ARGX
34.3B EUR
-14%
Country NL
Market Cap 3.2B USD
Net Margin
-681%
Country FR
Market Cap 6T USD
Net Margin
-21 040%
Country US
Market Cap 320.1B USD
Net Margin
9%
Country US
Market Cap 147.4B USD
Net Margin
13%
Country US
Market Cap 119.4B USD
Net Margin
-5%
Country US
Market Cap 113.8B USD
Net Margin
0%
Country US
Market Cap 94.1B EUR
Net Margin
-392%
Country AU
Market Cap 135.4B AUD
Net Margin
18%
Country US
Market Cap 82.6B USD
Net Margin
34%
Country US
Market Cap 39.3B EUR
Net Margin
-33%
Country NL
Market Cap 34.3B EUR
Net Margin
-14%
No Stocks Found

Merus NV
Glance View

Market Cap
3.2B USD
Industry
Biotechnology

Merus NV is a clinical-stage immuno-oncology company, which engages in the discovery and development of bispecific antibody therapeutics. The company is headquartered in Utrecht, Utrecht and currently employs 121 full-time employees. The company went IPO on 2016-05-19. The firm develops differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Biclonics format. Its products include, among others, MCLA-134 that is designed to bind to a combination of two immunomodulatory targets expressed by T cells, as well as MCLA-145 that is designed to bind to a tumor-associated target with an immunomodulatory target involved in checkpoint inhibition.

MRUS Intrinsic Value
25.32 USD
Overvaluation 45%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-680.6%
=
Net Income
-244.6m
/
Revenue
35.9m
What is the Net Margin of Merus NV?

Based on Merus NV's most recent financial statements, the company has Net Margin of -680.6%.